


=>

Uploading C:\Program Files\Stnexp\Queries\10613684h.str



chain nodes :

2 3 9 10 11 12 13 15 16 17 19 20 21 22 23 24 25 26 27 28 29
30 31 37 38

ring nodes :

1 4 5 6 7 8 40 41 42 43 44

chain bonds :

1-2 2-3 2-10 2-37 3-9 3-38 11-12 11-13 13-15 16-17 17-19 19-20 21-22
22-23 23-24 23-25 26-27 27-28 28-29 28-30 30-31

ring bonds :

1-4 1-8 4-5 5-6 6-7 7-8 40-41 40-44 41-42 42-43 43-44

exact/norm bonds :

3-9 11-12 11-13 13-15 16-17 17-19 19-20 21-22 22-23 23-24 23-25 26-27
27-28 28-29 28-30 30-31 40-41 40-44 41-42 42-43 43-44

exact bonds :

1-2 2-3 2-10 2-37 3-38

normalized bonds :

1-4 1-8 4-5 5-6 6-7 7-8

G1:H,Ak

G2:[*1],[*2],[*3],[*4]

G3:C,N

Match level :

1:Atom 2:CLASS 3:CLASS 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS
31:CLASS 37:CLASS
38:CLASS 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS

L16 STRUCTURE UPLOADED

=> s l16 full

FULL SEARCH INITIATED 23:26:22 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 20279 TO ITERATE


100.0% PROCESSED 20279 ITERATIONS
SEARCH TIME: 00.00.01

2 ANSWERS

L17 2 SEA SSS FUL L16

=> d 117 1-2


L17 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 256380-68-4 REGISTRY
CN Butanoic acid, 4-oxo-4-[[2-[4-(3-thienyl)phenyl]propyl]amino]-, methyl
ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H21 N O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L17 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN
RN 256380-67-3 REGISTRY
CN Propanoic acid, 3-oxo-3-[[2-[4-(3-thienyl)phenyl]propyl]amino]-, methyl
ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H19 N O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES
(Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.90	1148.97
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.30

FILE 'CAPLUS' ENTERED AT 23:26:51 ON 19 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Sep 2004 VOL 141 ISS 13
FILE LAST UPDATED: 17 Sep 2004 (20040917/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 117

L18 1 L17

=> d 118 ibib abs hitstr

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:84383 CAPLUS

DOCUMENT NUMBER: 132:122515

TITLE: Preparation of thienylphenylpropylamides, -carbamates,

-ureas, and related compounds as glutamate receptor potentiators.

INVENTOR(S): Arnold, Macklin Brian; Bleisch, Thomas John; Ornstein, Paul Leslie; Zarrinmayeh, Hamideh; Zimmerman, Dennis Michael; Bender, David Michael; Jones, Winton Dennis

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: Eur. Pat. Appl., 82 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 976744	A1	20000202	EP 1999-305981	19990728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2338916	AA	20000210	CA 1999-2338916	19990728
WO 2000006156	A1	20000210	WO 1999-US17126	19990728
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9951344	A1	20000221	AU 1999-51344	19990728
JP 2002521442	T2	20020716	JP 2000-562011	19990728
US 6617351	B1	20030909	US 2001-744412	20010123
US 2004097499	A1	20040520	US 2003-613684	20030703
PRIORITY APPLN. INFO.:			US 1998-94997P	P 19980731
			WO 1999-US17126	W 19990728
			US 2001-744412	A3 20010123

OTHER SOURCE(S): MARPAT 132:122515


AB R1CR5R8(CR6R7)qBR2 [B = CONRa, NRaCONRa; Ra = H, alkyl; q = 0, 1; R1 = (substituted) naphthyl, Ph, furyl, thienyl, pyridyl; R2 = H, alkyl, cycloalkyl, fluoroalkyl, alkenyl, alkoxyalkyl, phenylalkyl, heteroaryl, (substituted) Ph, etc.; R5-R8 = H, alkyl, aralkyl, alkenyl, aralkenyl, aryl], were prepared as nervous system agents (no data). Thus, (R)-2-(4-bromophenyl)-N-(tert-butoxycarbonyl)propylamine (preparation given) was stirred with K₂CO₃, Pd(Ph₃P)₄, and thiophene-3-boronic acid in dioxane/H₂O at 100° for 4 h to give 66% 2-[4-(3-thienyl)phenyl]propylamine trifluoroacetate. The latter in CH₂Cl₂ was treated with Et₃N and MeO₂CCl to give 2-[4-(3-thienyl)phenyl]-N-(methoxycarbonyl)propylamine.

IT 256380-67-3P 256380-68-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienylphenylpropylamides, -carbamates, -ureas, and related compds. as glutamate receptor potentiators)


RN 256380-67-3 CAPLUS

CN Propanoic acid, 3-oxo-3-[[2-[4-(3-thienyl)phenyl]propyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 256380-68-4 CAPLUS

CN Butanoic acid, 4-oxo-4-[[2-[4-(3-thienyl)phenyl]propyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



L19 STRUCTURE UPLOADED

=> s l19 full

FULL SEARCH INITIATED 23:28:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 20279 TO ITERATE


100.0% PROCESSED 20279 ITERATIONS
SEARCH TIME: 00.00.01

2 ANSWERS

L20 2 SEA SSS FUL L19

=> d 13 1-5 ibib abs hitstr

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:655594 CAPLUS
DOCUMENT NUMBER: 137:332741
TITLE: 4-Substituted D-Glutamic Acid Analogues: The First
Potent Inhibitors of Glutamate Racemase (MurI) Enzyme
with Antibacterial Activity
AUTHOR(S): de Dios, Alfonso; Prieto, Lourdes; Martin, Jose
Alfredo; Rubio, Almudena; Ezquerro, Jesus; Tebbe,
Mark; Lopez de Uralde, Beatriz; Martin, Justina;
Sanchez, Ana; LeTourneau, Deborah L.; McGee, James E.;
Boylan, Carole; Parr, Thomas R., Jr.; Smith, Michele
C.
CORPORATE SOURCE: Eli Lilly and Co., Lilly S.A., Alcobendas, Madrid,
28108, Spain
SOURCE: Journal of Medicinal Chemistry (2002), 45(20),
4559-4570
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The first potent inhibitors of glutamate racemase (MurI) enzyme that show whole cell antibacterial activity are described. Optically pure 4-substituted D-glutamic acid analogs with (2R,4S) stereochem. and bearing aryl-, heteroaryl-, cinnamyl-, or biaryl-Me substituents represent a novel class of glutamate racemase inhibitors. Exploration of the D-Glu core led to the identification of lead compds. 2-Naphthylmethyl derivative (I) was a potent competitive inhibitor of glutamate racemase activity ($K_i = 16$ nM, CD assay; $IC_{50} = 0.1$ μ g/mL high-performance liquid chromatog. (HPLC) assay). Thorough structure-activity relation (SAR) studies led to benzothienyl derivs. such as 69 and 74 with increased potency ($IC_{50} = 0.036$ and 0.01 μ g/mL, resp., HPLC assay). These compds. showed potent whole cell antibacterial activity against *S. pneumoniae* PN-R6, and good correlation with the enzyme assay. Some of the prepared substances showed efficacy in an in vivo murine thigh infection model against *Streptococcus pneumoniae*. Data described herein suggest that glutamate racemase may be a viable target for developing new antibacterial agents.

IT 400625-81-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and structure-activity relationship of D-glutamic acid analogs as potent inhibitors of glutamate racemase with antibacterial activity)

RN 400625-81-2 CAPLUS

CN D-Glutamic acid, 4-[[4-(3-thienyl)phenyl]methyl]-, hydrochloride, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:142656 CAPLUS

DOCUMENT NUMBER: 136:200471

TITLE: Preparation of D-glutamic acid derivatives as inhibitors of glutamate racemase

INVENTOR(S): De Dios, Alfonso; Ezquerra-Carrera, Jesus; McGee, James Eugene; Martin, Jose Alfredo; Prieto, Lourdes; Rubio-Esteban, Almudena; Smith, Michele Ceceil; Tebbe, Mark Joseph

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 83 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014261	A2	20020221	WO 2001-US22589	20010809
WO 2002014261	A3	20030327		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001078945	A5	20020225	AU 2001-78945	20010809
PRIORITY APPLN. INFO.:			ES 2000-2055	A 20000810
			US 2001-288361P	P 20010503
			WO 2001-US22589	W 20010809
OTHER SOURCE(S):	MARPAT 136:200471			
GI				




AB Compds. I [X is a bond, O, S, SO or SO₂; R₁ = (C₁-10)alkyl, (C₂-10)alkenyl or -alkynyl, (C₄-10)alkadienyl, carboxamido- or aminocarbonyl(C₁-8)alkyl which may be substituted by (C₃-10)cycloalkyl or by one or two (un)substituted aromatic groups, provided that when X represents a bond, R₁ can not represent a 3-phenyl-2-propenyl, 3-(4-chlorophenyl)-2-propenyl, 4-fluorobenzyl or 1-naphthylmethyl group] or their esters, amides or salts were prepared as inhibitors of glutamate racemase for use as antibiotics. Thus, (2R,4S)-2-amino-4-(2-naphthyl)methylpentanedioic acid was prepared by alkylation of D-Et N-(tert-butoxycarbonyl)pyroglutamate with 2-naphthylmethyl bromide, followed by ring cleavage/deprotection using LiOH in aqueous THF and workup.

IT **400625-81-2P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of D-glutamic acid derivs. as inhibitors of glutamate racemase)

RN 400625-81-2 CAPLUS

CN D-Glutamic acid, 4-[[4-(3-thienyl)phenyl]methyl]-, hydrochloride, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:319662 CAPLUS

DOCUMENT NUMBER: 134:336204

TITLE: Succinic acid derivative metallo-β-lactamase inhibitors, their preparation, and their use in treating bacterial infections

INVENTOR(S): Balkovec, James M.; Hammond, Gail; Greenlee, Mark L.; Olson, Steven H.; Rouen, Gregory P.; Epstein-Toney, Jeffrey H.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 136 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030149	A1	20010503	WO 2000-US29867	20001027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1227722	A1	20020807	EP 2000-975482	20001027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003513890	T2	20030415	JP 2001-532589	20001027
AU 762935	B2	20030710	AU 2001-13530	20001027
PRIORITY APPLN. INFO.:			US 1999-162369P	P 19991028
			WO 2000-US29867	W 20001027

OTHER SOURCE(S): MARPAT 134:336204

AB Substituted succinic acid metallo- β -lactamase inhibitors are provided which are useful potentiators of β -lactam antibiotics. Accordingly, the invention provides a method of treating bacterial infections in animals or humans which comprises administering, together with a β -lactam antibiotic, a therapeutically effective amount of a succinic acid derivative or pharmaceutically acceptable salt, prodrug, anhydride, or solvate thereof.


IT **337517-47-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (succinic acid derivative metallo- β -lactamase inhibitors, preparation, and use in treating bacterial infections)

RN 337517-47-2 CAPLUS

CN Butanedioic acid, 2-[[4-[2-[(4-methoxyphenyl)methyl]-3-thienyl]phenyl]methyl]-3-(phenylmethyl)-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **337518-43-1 337518-59-9**


. RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(succinic acid derivative metallo- β -lactamase inhibitors, preparation, and use in treating bacterial infections)

RN 337518-43-1 CAPLUS

CN Butanedioic acid, 2-(phenylmethyl)-3-[[4-(3-thienyl)phenyl]methyl]-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 337518-59-9 CAPLUS

CN Butanedioic acid, 2-(phenylmethyl)-3-[[3-(3-thienyl)phenyl]methyl]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:887871 CAPLUS

DOCUMENT NUMBER: 123:340965

TITLE: Preparation of dipeptide analogs as endothelin receptor antagonists.

INVENTOR(S): Saika, Hideyuki; Murata, Toshiki; Pitterna, Thomas; Frueh, Thomas; Svensson, Lene D.; Urade, Yoshihiro; Yamamura, Takaki; Okada, Toshikazu

PATENT ASSIGNEE(S): Japat Ltd., Switz.; Ciba-Geigy Japan Ltd.

SOURCE: PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9512611	A1	19950511	WO 1994-EP3418	19941017
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2173875	AA	19950511	CA 1994-2173875	19941017
AU 9478565	A1	19950523	AU 1994-78565	19941017
AU 691201	B2	19980514		
EP 728145	A1	19960828	EP 1994-929557	19941017
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9407933	A	19961126	BR 1994-7933	19941017
JP 09504302	T2	19970428	JP 1994-512982	19941017
RU 2126418	C1	19990220	RU 1996-112148	19941017
ZA 9408541	A	19950502	ZA 1994-8541	19941031
FI 9601804	A	19960430	FI 1996-1804	19960426
NO 9601725	A	19960429	NO 1996-1725	19960429
US 5780498	A	19980714	US 1996-637720	19960430
PRIORITY APPLN. INFO.:			EP 1993-810760	A 19931101
			WO 1994-EP3418	W 19941017

OTHER SOURCE(S): MARPAT 123:340965
GI



I

AB R1CONR2CH(CR3R31R311)C(X)YCHR4R5 [R1 = alkyl, cycloalkylalkyl, aralkyl, cycloalkyl, aryl, arylcycloalkyl, alkoxy, aryloxy, heteroaryl; R2 = H, alkyl, cycloalkyl, cycloalkylalkyl; R3, R31 = H, alkyl, cycloalkyl, aralkyl, aryl, heteroaryl; R3R31 = atoms to form a ring; R311 = H, alkyl, aryl; R2R311 = (CH2)_n, (CH2)_pAr; n = 1, 2, 3; p = 0, 1, 2; Ar = (hetero)arylene; X = O, S, NH, NHOH, CH2, etc.; Y = bond, O, CH2, imino; or X = (H, OH) and Y = bond, CH2; R4 = (CH2)_sAr1; s = 0, 1, 2, 3; Ar1 = (hetero)aryl; R5 = H, carboxy, (substituted) carboxamido, PO(OH)₂, tetrazolyl, CH2OH, CN], were prepared. Thus, title compound (I), prepared by solution phase means, inhibited endothelin-3 induced contraction of guinea pig trachea with pA₂ = 6.3. Drug formulations containing I are given.


IT 169545-88-4P 169545-89-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dipeptide analogs as endothelin receptor antagonists)


RN 169545-88-4 CAPLUS

CN L-Tryptophan, N-[N-(3,5-dimethylbenzoyl)-N,α-dimethyl-4-(3-thienyl)-D-phenylalanyl]- (9CI) (CA INDEX NAME)



RN 169547-49-3 CAPLUS
 CN L-Tryptophan, N-[N-(3,5-dimethylbenzoyl)-N, α -dimethyl-4-(3-thienyl)-L-phenylalanyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 1992:6554 CAPLUS
 DOCUMENT NUMBER: 116:6554
 TITLE: Pyrazole derivatives as angiotensin II-receptor antagonists, process for their preparation, and pharmaceutical compositions containing them
 INVENTOR(S): Bru-Magniez, Nicole; Nicolai, Eric; Teulon, Jean Marie
 PATENT ASSIGNEE(S): Laboratoires UPSA S. A., Fr.
 SOURCE: Eur. Pat. Appl., 93 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 449699	A2	19911002	EP 1991-400717	19910318
EP 449699	A3	19930407		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE


FR 2659655	A1	19910920	FR 1990-3485	19900319
FR 2659655	B1	19920724		
ZA 9101925	A	19920325	ZA 1991-1925	19910315
AU 9173591	A1	19910919	AU 1991-73591	19910318
CA 2038428	AA	19910920	CA 1991-2038428	19910318
JP 04234851	A2	19920824	JP 1991-78251	19910319
			FR 1990-3485	19900319

PRIORITY APPLN. INFO.:

OTHER SOURCE(S):

MARPAT 116:6554

GI




AB Pyrazoles I [R1 = alkyl, alkenyl, cycloalkyl; R2 = H, alkyl, haloalkyl, cycloalkyl, etc.; A = hydroxyalkyl, alkoxyalkyl, haloalkyl, CHO, CO2H, CONH2, etc.; R4 = NO2, NH2, CO2H, alkoxy carbonyl, various substituted Ph and thienyl groups] were prepared as cardiovascular agents, especially for treatment of hypertension or cardiac insufficiency. Thus, Et [1-methyl-3-butyl-4-(4-nitrobenzyl)pyrazol-5-yl]oxyacetate (preparation given) was hydrogenated over Raney Ni, and the resultant aminobenzyl compound condensed with 3,6-dichlorophthalic anhydride in MeCN, to give title compound II (isolated as dicyclohexylamine salt). II gave 96% displacement of [125I]-(Sar1,Tyr4,Ile8)-angiotensin II from rat suprarenal angiotensin II receptors in vitro at 10⁻⁵ M.

IT **137860-57-2P 137860-60-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for cardiovascular agents)


RN 137860-57-2 CAPLUS

CN Benzenepropanoic acid, 4-(2-cyano-3-thienyl)- α -(1-oxobutyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 137860-60-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[4-[2-(ethoxycarbonyl)-3-oxohexyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



=>

E ARNOLD MACKLIN BRIAN/AU 25

E1	1	ARNOLD M T/AU
E2	4	ARNOLD MACKLIN B/AU
E3	12 -->	ARNOLD MACKLIN BRIAN/AU
E4	1	ARNOLD MADELEINE C/AU
E5	1	ARNOLD MALCOLM/AU
E6	125	ARNOLD MANFRED/AU
E7	2	ARNOLD MARC/AU
E8	48	ARNOLD MARCEL/AU
E9	4	ARNOLD MARCO/AU
E10	2	ARNOLD MARCUS/AU
E11	1	ARNOLD MARGARET K/AU
E12	1	ARNOLD MARGARETE/AU
E13	4	ARNOLD MARGIE/AU
E14	1	ARNOLD MARGIT/AU
E15	1	ARNOLD MARIE ANTOINETTE/AU
E16	2	ARNOLD MARIE LUISE/AU
E17	3	ARNOLD MARILYN D/AU
E18	1	ARNOLD MARION/AU
E19	1	ARNOLD MARION D/AU
E20	3	ARNOLD MARION L/AU
E21	2	ARNOLD MARJORIE/AU
E22	1	ARNOLD MARJORIE E/AU
E23	1	ARNOLD MARJORIE LUCILLE/AU
E24	16	ARNOLD MARK/AU
E25	125	ARNOLD MARK A/AU

=> S (E2 OR E3) AND (?PHENYL(3A)THIENYL?)

4 "ARNOLD MACKLIN B"/AU
 12 "ARNOLD MACKLIN BRIAN"/AU
 754753 ?PHENYL
 1198880 PH
 9092 PHS
 1202899 PH
 (PH OR PHS)
 1809329 ?PHENYL
 (?PHENYL OR PH)
 25703 THIENYL?
 6415 ?PHENYL(3A)THIENYL?

L1 3 ("ARNOLD MACKLIN B"/AU OR "ARNOLD MACKLIN BRIAN"/AU) AND
 (?PHENYL(3A)THIENYL?)

=> DIS L1 1-

YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):Y

L1 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:98505 CAPLUS
 DN 132:137119
 TI Preparation of N-substituted sulfonamide derivatives for potentiating
 glutamate receptor function
 IN **Arnold, Macklin Brian**; Jones, Winton Dennis; Ornstein, Paul
 Leslie; Zarrinmayeh, Hamideh; Zimmerman, Dennis Michael
 PA Eli Lilly and Company, USA
 SO PCT Int. Appl., 206 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2000006537	A1	20000210	WO 1999-US17017	19990728
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9952355 A1 20000221 AU 1999-52355 19990728
US 6525099 B1 20030225 US 2001-744419 20010123

PRAI US 1998-94921P P 19980731
WO 1999-US17017 W 19990728

OS MARPAT 132:137119

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:98323 CAPLUS

DN 132:137177

TI Preparation of arylalkyl sulfonamides for potentiating of glutamate
receptor function

IN **Arnold, Macklin Brian**; Bender, David Michael; Fray, Andrew
Hendley; Jones, Winton Dennis; Ornstein, Paul Leslie; Simon, Richard Lee;
Zarrinmayeh, Hamideh; Zimmerman, Dennis Michael

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006157	A1	20000210	WO 1999-US17140	19990728
	W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2338864	AA	20000210	CA 1999-2338864	19990728
	AU 9952397	A1	20000221	AU 1999-52397	19990728
	EP 980864	A2	20000223	EP 1999-306006	19990728
	EP 980864	A3	20030709		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002521443	T2	20020716	JP 2000-562012	19990728
	US 6358981	B1	20020319	US 2001-744414	20010123
	US 2002115864	A1	20020822	US 2002-52988	20020118
	US 6515026	B2	20030204		
	US 2003171350	A1	20030911	US 2002-318483	20021212
	US 6713516	B2	20040330		
	US 2004157842	A1	20040812	US 2004-774284	20040206
PRAI	US 1998-94905P	P	19980731		
	WO 1999-US17140	W	19990728		
	US 2001-744414	A3	20010123		
	US 2002-52988	A3	20020118		
	US 2002-318483	A3	20021212		

OS MARPAT 132:137177

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:84383 CAPLUS
 DN 132:122515
 TI Preparation of thienylphenylpropylamides, -carbamates, -ureas, and related compounds as glutamate receptor potentiators.
 IN **Arnold, Macklin Brian**; Bleisch, Thomas John; Ornstein, Paul
 Leslie; Zarrinmayeh, Hamideh; Zimmerman, Dennis Michael; Bender, David
 Michael; Jones, Winton Dennis
 PA Eli Lilly and Company, USA
 SO Eur. Pat. Appl., 82 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 976744	A1	20000202	EP 1999-305981	19990728
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CA 2338916	AA	20000210	CA 1999-2338916	19990728
	WO 2000006156	A1	20000210	WO 1999-US17126	19990728
	W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9951344	A1	20000221	AU 1999-51344	19990728
	JP 2002521442	T2	20020716	JP 2000-562011	19990728
	US 6617351	B1	20030909	US 2001-744412	20010123
	US 2004097499	A1	20040520	US 2003-613684	20030703
PRAI	US 1998-94997P	P	19980731		
	WO 1999-US17126	W	19990728		
	US 2001-744412	A3	20010123		

OS MARPAT 132:122515

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT